4 results
Primary objective* To demonstrate the effect of ACT-293987 on time to first morbidity and mortality (MM) event in patients with pulmonary arterial hypertension (PAH).Secondary objective * To evaluate the effect of ACT-293987 on exercise capacity and…
1. Determining whether or not the vitamin K tablets have the same biological availability in humans as the vitamin K solution has.2. Determining whether or not the vitamin K tablets are as effective as the vitamin K solution is.
To assess the long-term safety and tolerability of selexipag (ACT-293987) in patients with pulmonary arterial hypertension (PAH).
VIKS-2A:To determine the optimal dosage of vitamin K for supplementation to obtain a stable anticoagulation effect.VIKS-2B:To determine whether supplementation with the found optimal dosage of vitamin K from study VIKS-2A will decrease the number of…